United Therapeutics Corporation Available-for-sale Securities, Amortized Cost Basis
United Therapeutics Corporation (UTHR) had Available-for-sale Securities, Amortized Cost Basis of $740.40 million as of 2017-12-31, per its 10-K filed 2018-02-21.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-02-21
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $740.40M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $481.00M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $341.90M.
- 2017-03-31: Available-for-sale Securities, Amortized Cost Basis $311.80M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2017-12-31 | $740.40M 10-K · filed 2018-02-21 |
| 2017-09-30 | $481.00M 10-Q · filed 2017-10-25 |
| 2017-06-30 | $341.90M 10-Q · filed 2017-07-27 |
| 2017-03-31 | $311.80M 10-Q · filed 2017-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |